Stress hypERactivation in the beta-cell

Sonya G. Fonseca

Novartis Institutes for Biomedical Research

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/pgfe_pp

Part of the Genetics and Genomics Commons

Repository Citation

Stress hypERactivation in the β-cell

Sonya G. Fonseca,1,* Fumihiko Urano,2,3 Mark Burcin1 and Jesper Gromada1

1Cardiovascular and Metabolism Division; Novartis Institutes for Biomedical Research; Cambridge, MA USA; 2Program in Gene Function and Expression; and 3Program in Molecular Medicine; University of Massachusetts Medical School; Worcester, MA USA

Key words: ER stress, UPR, diabetes, β-cell, Wolfram syndrome, WFS1

In pancreatic β-cells, the endoplasmic reticulum (ER) is the crucial site for insulin biosynthesis, as this is where the protein-folding machinery for secretory proteins is localized. Perturbations to ER function of the β-cell, such as a high demand for insulin secretion, can lead to an imbalance in protein homeostasis and lead to ER stress. This stress can be mitigated by an adaptive, cellular response, the Unfolded Protein Response (UPR). UPR activation is vital to the survival of β-cells, as these cells represent one of the most susceptible tissues for ER stress, due to their highly secretory function. However, in some cases, this response is not sufficient to relieve stress, leading to apoptosis and contributing to the pathogenesis of diabetes. Recent evidence shows that ER stress plays a significant role in both type 1 and type 2 diabetes. In this review, we outline the mechanisms of ER stress-mediated β-cell death and focus on the role of ER stress in various forms of diabetes, particularly a genetic form of diabetes called Wolfram Syndrome.

Introduction

Pancreatic β-cells have the specialized function of regulating glucose homeostasis by synthesizing and secreting the hormone insulin.1 Newly synthesized insulin is not immediately functional—it must be folded into its proper three-dimensional structure. The endoplasmic reticulum (ER) has an essential role in the processing and assembly of insulin, with its complex of chaperones, such as immunoglobulin heavy chain-binding protein (BiP) and foldases, such as protein disulfide isomerase (PDI).

The sensitive folding environment of the ER can be disrupted by physiological processes, such as post-prandial insulin biosynthesis which places a heavy load on the ER, as well as a pathological exposure to viruses, toxins, cytokines and mutant protein expression.2,3 ER stress occurs when the ER exceeds its folding capacity with such disruptions, leading to an overall dysregulation of protein homeostasis, reflected as reduced maintenance of the quality and quantity of protein and an accumulation of unfolded/misfolded proteins that cannot be processed through the secretory pathway. This stress elicits an ER-to-nucleus signaling cascade, the Unfolded Protein Response (UPR), which mitigates stress in three distinct manners: (1) enhancement of folding activity through increased chaperone/foldase expression, (2) reduction of ER workload through general translational attenuation and (3) clearance of protein aggregation and residual unfolded proteins through ER-associated protein degradation (ERAD). When the UPR does not adequately reduce stress and return the cell to a state of protein homeostasis, the cell undergoes apoptosis.4

β-cell apoptosis has recently been shown not only to be a component of type 1 diabetes, but also type 2 diabetes.5 In type 1 diabetes, β-cells are selectively destroyed by a combination of autoimmune and inflammatory processes leading to an absolute insulin deficiency, whereas in type 2 diabetes, resistance to insulin in peripheral tissues accompanied by a reduction in endogenous insulin secretion leads to relative insulin deficiency.6,7 Recent data suggests that ER stress contributes to β-cell death, autoimmune and insulin resistance in the pathogenesis of diabetes. This review outlines the delicate balance of β-cell protein homeostasis and the mechanisms of ER stress-mediated β-cell dysfunction and death.

The ER Stress Signaling Triad

The UPR has three master transducers which serve to mitigate stress: inositol requiring 1 (IRE1), PKR-like kinase (PERK), and activating transcription factor 6 (ATF6). The ER chaperone BiP binds to each of these to maintain them in an inactive state until stress: inositol requiring 1 (IRE1), PKR-like kinase (PERK), and activating transcription factor 6 (ATF6). The ER chaperone BiP binds to each of these to maintain them in an inactive state until stress is present (i.e., unfolded and misfolded proteins accumulate in the ER lumen) (Fig. 1).

IRE1, is a type 1 ER transmembrane kinase that has endoribonuclease activity.8 Mammalian cells have two isoforms, IRE1α and IRE1β, which both have functions as sensors of the UPR. IRE1α is ubiquitously expressed, while the β isoform is uniquely expressed in the epithelial cells of the gastrointestinal tract.9 When unfolded or misfolded proteins accumulate in the ER, IRE1α dimerizes and undergoes trans-autophosphorylation to become active. Activation of its kinase domain leads to activation of its endoribonuclease function, whereby the mRNA of the transcription factor X-box protein binding 1 (XBP1) is unconventionally spliced. Spliced XBP1 translocates to the nucleus where it upregulates a variety of UPR target genes encoding ERAD components, as well as foldases such as PDI.10

PERK, also a type 1 ER transmembrane kinase, senses stress in its N-terminal luminal domain. When released from BiP, PERK dimerizes and undergoes trans-autophosphorylation. Activated PERK, directly phosphorylates the α subunit of eukaryotic initiation factor 2 (eIF2α), its only identified target.11 This in turn inhibits general protein synthesis, while preferentially increasing

*Correspondence to: Sonya Fonseca; Email: Sonya.Fonseca@novartis.com
Submitted: 10/14/09; Accepted: 10/28/09
Previously published online: www.landesbioscience.com/journals/islets/article/10456

www.landesbioscience.com Islets 1:1-9; January/February 2010; © 2010 Landes Bioscience
Insulin is secreted by the β-cell in response to acute hyperglycemia which occurs post-prandially. This secretory response stimulates the biosynthesis and translation of the precursor proinsulin in the ER, in which there is approximately a 10-fold increase in synthesis from a low-glucose (<3 mM) to higher glucose concentrations. Preproinsulin is synthesized in the cytoplasm and co-translationally translocated into the ER. Preproinsulin’s signal peptide is cleaved in the ER to generate proinsulin, which then undergoes precise folding in the lumen of the ER, where three disulphide bonds are formed. Once proinsulin is properly folded, it is transported to the Golgi and packaged into secretory granules, where it is processed to yield mature insulin.

β-cells, due to their heavy engagement in insulin secretion, have been found to be very sensitive to disruptions in ER homeostasis. This is reflected in the fact that these cells have a highly developed ER and a high expression of ER stress transducer proteins such as IRE1α, PERK, total XBP1, GRP94 and BiP. Thus, while β-cells have a robust ER signaling system, they are sensitive to disruptions in a system that is already at capacity. These cells are exposed to frequent energy fluctuations (i.e., intermittent changes in blood glucose levels), and thus require precise and proper folding of proinsulin to respond to such changes. Thus, any imbalance between the load of insulin translation placed on the ER and the ER folding capacity will lead to ER stress and a disruption in protein homeostasis in these cells.

The IRE1-XBP1 signaling pathway is important for ER expansion and the IRE1α isoform is highly expressed in the pancreas. β-cells have been shown to have a baseline phosphorylation of IRE1α, illustrating the high activity of the UPR in these cells. Suppression of IRE1 activity inhibits proinsulin biosynthesis, while activation enhances insulin biosynthesis in an XBP1-independent manner. While the downstream targets of this unique IRE1 pathway have yet to be identified, it is known that the ER-resident oxidoreductase, endoplasmic oxidoreductin 1 (ERO1α) is upregulated. ERO1α is an activator of PDI, which is critical in catalyzing the formation of disulphide bonds during protein folding in the ER. Thus, IRE1 activation may enhance insulin biosynthesis through the upregulation of ERO1α which in turn is responsible for the vital formation of the three disulphide bonds in proinsulin through PDI activation.

PERK is also highly expressed in islets. PERK activation (i.e., phosphorylation) negatively regulates insulin biosynthesis. In PERK null mice islets, high glucose treatment-induced insulin biosynthesis was enhanced compared to control littermate islets. In β-cell-specific PERK null mice, a connection has been made between the expression of PERK and β-cell development and proliferation. PERK mutations are also the cause of a genetic form of diabetes called Wolcott-Rallison syndrome. Thus, the IRE1 pathway (positive regulator) and PERK pathway (negative regulator) work together to precisely regulate insulin output, again highlighting the importance of the UPR in the β-cell.

Recently, it has been demonstrated that ATF6 may also have a function in regulating insulin. Under ER stress, ATF6 is activated, leading to a decrease in insulin gene expression. This suggests that ATF6 may have dual functions: positive regulation of chaperones and negative regulation of insulin promoter activity. The involvement of the UPR triad (i.e., IRE1, PERK and ATF6) in β-cell proteostasis and insulin biosynthesis illustrates
the extensive crosstalk in the UPR network which precisely regulates protein secretion.

**HypERActivation of the UPR**

There are two protein quality control outputs of the UPR: homeostatic and apoptotic. The goal of the UPR is to restore protein homeostasis, however, this may involve apoptosis to ensure that highly stressed cells do not produce damaged (i.e., misfolded) secretory proteins. Indeed, ER stress can be classified into two groups: physiological and pathological. Physiological stress occurs when there is a high demand for protein load. This is acute stress that is readily mitigated by the UPR. One example of this is acute post-prandial ER stress in the β-cell—there is a high demand for insulin biosynthesis following food intake which increases the folding load of the ER. This stress is actually favorable to the β-cell.

When ER stress is severe or prolonged such that it cannot be resolved by the UPR, cell death occurs by apoptosis. This prolonged stress can be attributed to an insufficient UPR response, or hyperactivation of a component of the UPR (i.e., the UPR is not properly regulated). There are at least three pathways involved in ER stress-dependent apoptosis which culminate in the activation of the effector cysteine protease caspase-3: (1) transcriptional activation of CHOP which represses Bcl-2; (2) activation of the Jun N-terminal kinase (JNK) by IRE1-dependent recruitment of the adaptor protein, TRAF2; and (3) activation of caspase-12 (caspase-4 in humans).

Physiological ER stress in the β-cell is beneficial and leads to the highly-regulated activation of insulin biosynthesis. This is attributable to acute hyperglycemia. Physiological stress can also be referred to as Stimulus-Coupling Adaptation to ER Folding (SCAEF). In this state, the downstream apoptotic factors of the UPR are not activated. However, exposure of these cells to chronic, prolonged hyperglycemia induces pathological ER stress which impairs ER function. This leads to β-cell dysfunction and eventually cell death because this pathological stress leads to hyperactivation of the UPR. An example of this can be seen when β-cells are treated with an inhibitor of eIF2α dephosphorylation, salubrinal. Persistent activation of the PERK-eIF2α pathway is deleterious to these cells, most likely due to the inhibition of general translation. Hyperactivation of IRE1, as measured by its chronic phosphorylation, also leads to cell death via the JNK pathway and the degradation of mRNAs encoding key stress signaling regulators, such as chaperones. Thus, hyperactivation of any of the UPR triad pathways is detrimental, even the ATF6 pathway which controls the expression of the proapoptotic CHOP transcription factor. In addition to treatment of β-cells with chronic high glucose, there are other causes of pathological ER stress in the cells: exposure to long-chain free fatty acids (e.g., palmitate), hyperinsulinemia which occurs in the pre-diabetic stage, glucose deprivation, islet amyloid polypeptide (IAPP) expression and exposure to inflammatory cytokines such as IL-1β and IFNγ.

One may consider that through the evolution of the β-cell, there should have been the development of a robust defense mechanism against ER stress-mediated apoptotic outcomes. However, because of the constant demands of insulin biosynthesis, this has rendered the β-cell dependent on a highly efficient UPR. Recent findings show that β-cells are highly susceptible to ER stress-mediated apoptosis and this can be a cause of diabetes.

**Wolfram Syndrome: A Model of ER Stress-Mediated β-Cell Death**

Current evidence suggests that ER stress is one of the molecular mechanisms of β-cell dysfunction contributing to the pathogenesis of diabetes. The relationship of ER stress and diabetes can clearly be seen in a rare, autosomal recessive form of juvenile diabetes, Wolfram syndrome.

The first report of this disease was documented in 1938 when Wolfram and Wagener analyzed eight siblings, four of which had a combination of juvenile diabetes and optical atrophy. This disease has been characterized as having four cardinal components: diabetes insipidus, diabetes mellitus, optic atrophy and deafness, of which only diabetes mellitus and optical atrophy are required to make a diagnosis. Diabetes mellitus typically becomes symptomatic in the first decade of life, with a mean age of 6, while optic atrophy follows in the second decade (mean age of 12). (Fig. 3). Of the other symptoms, 73% of patients develop diabetes insipidus, 62% develop sensorineural deafness, 58% develop renal tract complications, and 62% develop neurological defects. A high percentage of patients also present...
with urinary tract abnormalities and neuropsychiatric impairment,\textsuperscript{61} while powdered cataract and retinopathy can also be seen in a fraction of these patients.\textsuperscript{60,61} (Fig. 3) Mortality occurs in approximately 65\% of patients before the age of 35,\textsuperscript{59} primarily caused by central respiratory and renal failure, as well as brain stem atrophy.\textsuperscript{62} While generally considered a rare disease in most countries, for example in the UK the prevalence is 1/770,000,\textsuperscript{59} with a carrier frequency of 1/354.\textsuperscript{63} Some countries like Japan and Lebanon have higher incidences.\textsuperscript{61,64}

The nuclear gene responsible for this syndrome which spans 33.4 kb of genomic DNA was identified by two separate groups in 1998 and named WFS1.\textsuperscript{65,66} To date, there are over 130 distinct mutations in WFS1 identified in patients.\textsuperscript{67-75} While there has been no descript mutational hotspot noted, most are located in the region which encodes the transmembrane and C-terminal domain of the protein, exon 8.\textsuperscript{67,70} A majority of patients are compound heterozygotes for two mutations, most of which have one mutation that alters the C-terminal tail.\textsuperscript{70} Even mutations of the last seven amino acids of the C-terminal lead to a full disease phenotype, suggesting that this region may be important to the function of WFS1.\textsuperscript{74} In a survey of patient mutations, 35\% were missense, 25\% nonsense, 21\% frameshift, 13\% inframe deletions/insertions and 3\% splice-site.\textsuperscript{75} It is challenging to make conclusive genotype-phenotype relationships, although severely inactivating mutations, for example a premature stop codon, seem to elicit more severe symptoms than mildly inactivating ones, such as missense mutations, and mutations outside of exon 8 typically present with a more mild phenotype.\textsuperscript{60,63} WFS1 mutations in patients with Wolfrnam syndrome thus lead to a loss-of-function of WFS1. It must be noted that the heterogeneity of this disease has led to the recent discovery of another locus for this disease, WFS2/Miner1/CISD2, which accounts for only a fraction of Wolfrnam syndrome cases.\textsuperscript{76-78}

WFS1 is a 100 kDa glycosylated protein that is localized to the ER membrane.\textsuperscript{79} Its N-terminal is cytoplasmic, while its C-terminal is located in the ER lumen. The C-terminal of WFS1 is highly conserved in the mouse, rat and human. N-glycosylation is its only predicted post-translational modification and it is projected to have nine transmembrane domains.\textsuperscript{80} There is evidence which suggests that WFS1 may function as a calcium channel; ectopic expression of WFS1 produces an increase in calcium concentration in the cytosol and exhibits cation-selective channel activities in the ER membrane.\textsuperscript{81} This suggests that WFS1 may function in ER calcium homeostasis. WFS1 may also regulate ion homeostasis of the canalicular reticulum.\textsuperscript{82} Hence, inactivation or suppression of WFS1 may cause an imbalance in ER calcium homeostasis.

While ubiquitously expressed, WFS1 is highly expressed in the pancreas.\textsuperscript{65} Although Wolfram syndrome patients are generally not obese, nor do they have insulinis, postmortem studies reveal a selective loss of $\beta$-cells in their pancreatic islets.\textsuperscript{82} In line with this, WFS1 is not only highly expressed in $\beta$-cells, but is localized to these cells in the pancreas, with no detectable expression in the various other pancreatic cell types.\textsuperscript{83}

While it was known that the loss of $\beta$-cells in patients is not auto-immune related, the cause of cell death has been elusive until recently. WFS1 has been shown to be a component of IRE1 and PERK signaling and is important in the maintenance of ER homeostasis, particularly in $\beta$-cells.\textsuperscript{83} It has also been reported that glucose-induced cytosolic calcium production is lower in the islets of WFS1 knockout mouse as compared to controls.\textsuperscript{84} Suppression of WFS1 leads to high levels of ER stress in $\beta$-cells, suggesting that WFS1 protects $\beta$-cells against ER stress and, conversely, chronic ER stress is caused by a loss-of-function of WFS1 protein.\textsuperscript{83-86} Together, these findings suggest that a lack of functional WFS1 causes abnormal calcium homeostasis in the ER, elicits ER stress, and triggers apoptosis in pancreatic $\beta$-cells. This suggests that Wolfram syndrome can be attributed to chronic, unresolved ER stress in the $\beta$-cell.

The precise function of WFS1 in ER stress signaling has remained somewhat elusive. However, there is several lines of evidence which suggest that WFS1 may be a multi-functional protein. For example, it was reported that the C-terminal and transmembrane domains of WFS1 interact with the Na⁺/K⁺ ATPase $\beta_1$ subunit. WFS1 mutations thus disrupt this interaction which is speculated to decrease $\alpha_1$ and $\beta_1$ sodium pump subunit expression in $\beta$-cells leading to cell dysfunction.\textsuperscript{87} The question remains whether this interaction is a result of ER stress and is it primary or secondary to the pathology of Wolfram syndrome. In addition, WFS1 can bind the Ca²⁺/CaM complex, which suggests that WFS1 may modulate the actions of Ca²⁺ as an intracellular second messenger.\textsuperscript{88} Impairment of binding of this complex may also cause a loss-of-function of WFS1. There is also preliminary evidence that WFS1 regulates a key transcription factor of the UPR, ATF6, through the ubiquitin-proteasome pathway. Higher expression of WFS1 in $\beta$-cells, prevents hyperactivation of ER stress signaling.
in these cells which are particularly sensitive to disruption of ER homeostasis and dysregulation of the UPR. Thus, WFS1 has a role in protecting β-cells from premature death by acting as an ER stress signaling suppressor.

Interestingly, WFS1 may also have a role in insulin biosynthesis and secretion. WFS1 expression is induced during glucose-induced insulin secretion.27,83 This data, along with the localization of WFS1 to the β-cell, suggests that WFS1 is an important component of proinsulin folding and processing in the ER of the β-cell. The role of WFS1 as a regulator of the ATF6 branch of the UPR may also be related to its role in regulating insulin biosynthesis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.

Studying rare diseases, such as Wolfram syndrome, can help lead to answers to more common diseases, because there is a single genetic defect which can allow researchers to focus on the function of a gene or protein that is often involved in common diseases. Indeed, a link can be made between Wolfram syndrome and common forms of diabetes in which loss of β-cell function is associated with a decreased β-cell mass via apoptosis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.

Studying rare diseases, such as Wolfram syndrome, can help lead to answers to more common diseases, because there is a single genetic defect which can allow researchers to focus on the function of a gene or protein that is often involved in common diseases. Indeed, a link can be made between Wolfram syndrome and common forms of diabetes in which loss of β-cell function is associated with a decreased β-cell mass via apoptosis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.

Studying rare diseases, such as Wolfram syndrome, can help lead to answers to more common diseases, because there is a single genetic defect which can allow researchers to focus on the function of a gene or protein that is often involved in common diseases. Indeed, a link can be made between Wolfram syndrome and common forms of diabetes in which loss of β-cell function is associated with a decreased β-cell mass via apoptosis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.

Studying rare diseases, such as Wolfram syndrome, can help lead to answers to more common diseases, because there is a single genetic defect which can allow researchers to focus on the function of a gene or protein that is often involved in common diseases. Indeed, a link can be made between Wolfram syndrome and common forms of diabetes in which loss of β-cell function is associated with a decreased β-cell mass via apoptosis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.

Studying rare diseases, such as Wolfram syndrome, can help lead to answers to more common diseases, because there is a single genetic defect which can allow researchers to focus on the function of a gene or protein that is often involved in common diseases. Indeed, a link can be made between Wolfram syndrome and common forms of diabetes in which loss of β-cell function is associated with a decreased β-cell mass via apoptosis and/or secretion, demonstrating the multi-functional aspect of this protein. Indeed, activation of ATF6 by ER stress has been shown to decrease insulin gene expression.33 ATF6 polymorphisms and haplotypes are also associated with impaired glucose homeostasis and type 2 diabetes.39 Thus, this raises the possibility that the interaction between WFS1 and ATF6 not only functions as a method to regulate the UPR, but also insulin biosynthesis: by restricting ATF6 activation, WFS1 prevents ATF6-mediated suppression of insulin gene expression.
high glucose and long-chain free fatty acids) has recently been shown to lead to excessive ER stress which may perpetuate the cycle of β-cell exhaustion and the strain already placed on the ER of the β-cell by hyperinsulinemia. In addition, ER stress is involved in insulin resistance of the liver, muscle and adipose.

Figure 4 summarizes the link between ER stress and the different forms of diabetes.

Future Perspectives

There is abundant evidence to support the role of ER stress and stress signaling in the physiological function of the β-cell, as well as the pathogenesis of different forms of diabetes. This has been exquisitely demonstrated through studies of monogenic forms of diabetes such as Wolfram syndrome. Such studies have allowed researchers to better understand components of the UPR pathway and their functions, as well as the importance of ER stress signaling in the pancreatic β-cell. This has been highlighted by the link between the functional absence of a UPR component, such as WFS1, and ER stress-mediated β-cell death.

There are several aspects of ER stress signaling which need to be further investigated in order to appreciate the role of this pathway in the pathogenesis of diabetes. This will also answer the question whether components of the UPR, such as WFS1, would make “druggable” targets for the treatment of various forms of diabetes—this would address the issue of whether β-cells can be protected from hyper- or hypo-activation of ER stress signaling pathways without compromising their primary function as glucose sensors and regulators. The areas of research which need further exploration include: (1) understanding the mechanisms of the UPR in regulating insulin biosynthesis and secretion, (2) understanding the mechanisms of UPR activation in the β-cell by glucolipotox and (3) further defining the key regulators, pathways, and crosstalk of UPR-mediated apoptosis specific to the β-cell. Such research will further strengthen the link between ER stress, β-cell death, and the pathogenesis of diabetes.

Acknowledgements

Laboratory of F. Urano is supported by grants from NIH-NIDDK (R01DK067493), the Diabetes and Endocrinology Research Center at the University of Massachusetts Medical School, the Juvenile Diabetes Research Foundation International, Massachusetts Technology Transfer Center, and the Worcester Foundation for Biomedical Research.

References

Figure 5. Summary of the link between ER stress and different forms of diabetes. The three forms of diabetes: genetic, type 1 and type 2 can all be linked to ER stress and UPR-mediated apoptosis of the β-cell.


